Gain Contingency, Number of Defendants

No definition available.

Name:	pfe_GainContingencyNumberofDefendants
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Gain Contingency, Patents Allegedly Infringed upon, Number Due to Expire in December 2020

+ References

No definition available.

+ Details

Name:	pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2020
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Gain Contingency, Patents Allegedly Infringed upon, Number Due to Expire in December 2025

+ References

No definition available.

+ Details

Name:	pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2025
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Gain Contingency, Patents Found Not Infringed upon, Number Due To Expire In 2019

+ References

No definition available.

+ Details

Name:	pfe_GainContingencyPatentsFoundNotInfringeduponNumberDueToExpireIn2019
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Gain Contingency, Patents Found Not Infringed upon, Number Due To Expire In 2032

+ References

No definition available.

+ Details

Name:	pfe_GainContingencyPatentsFoundNotInfringeduponNumberDueToExpireIn2032
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_GainContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of entity's patents that another entity has allegedly infringed.

+ References

No definition available.

+ Details

Name:	us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of entity's patents that another entity was found to have infringed.

+ References

No definition available.

+ Details

Name:	us-gaap_GainContingencyPatentsFoundInfringedUponNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of entity's patents that another entity was found not to have infringed.

+ References

No definition available.

+ Details

Name:	us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=pfe_BosulifMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_WyethVersusSunMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=pfe_PrecedexPremixMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_HospiraVersusAmnealPharmaceuticalsLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_HospiraVersusParMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_HospiraVersusGlandMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_HospiraVersusHengruiMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_HospiraVersusBaxterMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=pfe_XeljanzMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_PfizerVersusMicroLabsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_PfizerVersusZydusMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_PfizerVersusPrinstonandBreckenridgeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_PfizerVersusBreckenridgeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=pfe_ToviazMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=pfe_ToviazCompositionofmatterPatentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=pfe_EliquisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_PfizerandBMSVersusSeveralGenericManufacturersMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Contingencies and Certain Commitments (Action In Which We Are the Plaintiff) (Details)	1 Months Ended													3 Months Ended
	Jun. 30, 2018 Patents	Feb. 28, 2018 Patents	Jan. 31, 2018 Patents	Dec. 31, 2017 Patents	Oct. 31, 2017 Patents	Sep. 30, 2017 Patents	Jul. 31, 2017 Patents	Mar. 31, 2017 Patents	Feb. 28, 2017 Patents	Aug. 31, 2016 Patents	Jul. 31, 2016 Patents	Jan. 31, 2016 Patents	Jun. 30, 2015 Patents	Apr. 30, 2017 Defendant Patents
Patent Infringement [Member] \| Judicial Ruling [Member]
Gain Contingencies [Line Items]
Number of patents infringed upon	1
Bosulif [Member] \| Wyeth Versus Sun [Member] \| Patent Infringement [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon						2
Precedex Premix [Member] \| Hospira Versus Amneal Pharmaceuticals LLC [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents found not infringed upon													4
Precedex Premix [Member] \| Hospira Versus Amneal Pharmaceuticals LLC [Member] \| Settled Litigation [Member]
Gain Contingencies [Line Items]
Number of patents infringed upon			1
Number of patents found not infringed upon			3
Precedex Premix [Member] \| Hospira Versus Par [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents found not infringed upon										4
Precedex Premix [Member] \| Hospira Versus Gland [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon		4
Number of patents found not infringed upon				6
Precedex Premix [Member] \| Hospira Versus Hengrui [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon		4
Number of patents found not infringed upon				6
Precedex Premix [Member] \| Hospira Versus Baxter [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents found not infringed upon		4
Number of patents due to expire in 2019		1
Number of patents due to expire in 2032		3
Xeljanz [Member] \| Pfizer Versus MicroLabs [Member] \| Patent Infringement [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon									3
Xeljanz [Member] \| Pfizer Versus Zydus [Member] \| Patent Infringement [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon								3
Xeljanz [Member] \| Pfizer Versus Prinston and Breckenridge [Member] \| Patent Infringement [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon								2
Xeljanz [Member] \| Pfizer Versus Breckenridge [Member] \| Patent Infringement [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon					4
Number of patents allegedly infringed upon due to expire in December 2020					3
Number of patents allegedly infringed upon due to expire in December 2025					1
Toviaz [Member] \| Pfizer Versus Mylan Laboratories and Accord Healthcare Inc. [Member] \| Patent Infringement [Member] \| Judicial Ruling [Member]
Gain Contingencies [Line Items]
Number of patents found not infringed upon							5
Toviaz [Member] \| Pfizer Versus Mylan Laboratories and Accord Healthcare Inc. [Member] \| Patent Infringement [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon											5	5
Toviaz Composition-of-matter Patents [Member] \| Pfizer Versus Mylan Laboratories and Accord Healthcare Inc. [Member] \| Patent Infringement [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents infringed upon												3
Eliquis [Member] \| Pfizer and BMS Versus Several Generic Manufacturers [Member] \| Patent Infringement [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon														3
Number of defendants \| Defendant														25